Community Trust & Investment Co. Raises Stock Position in Amgen Inc. (NASDAQ:AMGN)

Community Trust & Investment Co. boosted its holdings in Amgen Inc. (NASDAQ:AMGNFree Report) by 4.2% in the second quarter, HoldingsChannel reports. The institutional investor owned 13,772 shares of the medical research company’s stock after purchasing an additional 550 shares during the quarter. Community Trust & Investment Co.’s holdings in Amgen were worth $3,058,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of AMGN. Roundview Capital LLC raised its stake in shares of Amgen by 1.3% during the first quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock valued at $2,027,000 after acquiring an additional 107 shares in the last quarter. Merit Financial Group LLC increased its holdings in Amgen by 39.2% during the first quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock valued at $555,000 after buying an additional 647 shares during the period. Ergoteles LLC purchased a new position in Amgen during the first quarter valued at approximately $219,000. First Western Trust Bank purchased a new position in Amgen during the first quarter valued at approximately $334,000. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in Amgen by 2.1% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock valued at $5,970,000 after buying an additional 513 shares during the period. Hedge funds and other institutional investors own 74.44% of the company’s stock.

Insider Buying and Selling

In related news, EVP Murdo Gordon sold 9,558 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $262.43, for a total transaction of $2,508,305.94. Following the sale, the executive vice president now owns 44,308 shares of the company’s stock, valued at $11,627,748.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.57% of the stock is owned by insiders.

Amgen Stock Performance

NASDAQ AMGN traded up $0.15 during trading on Tuesday, reaching $263.30. The company’s stock had a trading volume of 458,133 shares, compared to its average volume of 2,447,841. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $296.67. The company has a debt-to-equity ratio of 8.76, a quick ratio of 2.48 and a current ratio of 2.77. The business’s fifty day moving average price is $248.12 and its 200-day moving average price is $237.72. The firm has a market cap of $140.84 billion, a price-to-earnings ratio of 17.74, a P/E/G ratio of 3.28 and a beta of 0.61.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings results on Thursday, August 3rd. The medical research company reported $5.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.44 by $0.56. Amgen had a net margin of 30.02% and a return on equity of 196.60%. The business had revenue of $7 billion for the quarter, compared to analyst estimates of $6.66 billion. During the same period in the previous year, the business posted $4.65 earnings per share. The business’s revenue was up 6.2% compared to the same quarter last year. As a group, analysts anticipate that Amgen Inc. will post 18.35 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Friday, August 18th were issued a dividend of $2.13 per share. This represents a $8.52 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date was Thursday, August 17th. Amgen’s dividend payout ratio is currently 57.45%.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of recent analyst reports. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 8th. Credit Suisse Group reduced their price target on Amgen from $220.00 to $200.00 in a research report on Wednesday, July 12th. Truist Financial reaffirmed a “hold” rating and set a $260.00 price target on shares of Amgen in a research report on Tuesday, September 5th. Oppenheimer reissued an “outperform” rating and issued a $280.00 target price on shares of Amgen in a research report on Tuesday, July 25th. Finally, HSBC began coverage on Amgen in a research report on Wednesday, September 6th. They issued a “buy” rating and a $320.00 target price on the stock. Two analysts have rated the stock with a sell rating, five have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $265.44.

Get Our Latest Stock Report on Amgen

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.